{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:10:56Z","timestamp":1788865856700,"version":"build-2803163510"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.01115","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T08:44:15Z","timestamp":1595839455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Internalized Functional DNA Aptamers as Alternative Cancer Therapies"],"prefix":"10.3389","volume":"11","author":[{"given":"Morgan L.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie M.","family":"Wagstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.nano.2017.04.002","article-title":"A novel chemotherapy drug-free delivery system composed of three therapeutic aptamers for the treatment of prostate and breast cancers in vitro and in vivo","volume":"13","author":"Abnous","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102511","article-title":"Updates on Aptamer Research","volume":"20","author":"Ali","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.phrs.2015.11.027","article-title":"Targeting VEGF in eye neovascularization: What\u2019s new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development","volume":"103","author":"Amadio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0134957","DOI":"10.1371\/journal.pone.0134957","article-title":"Selective Targeting to Glioma with Nucleic Acid Aptamers","volume":"10","author":"Aptekar","year":"2015","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00109-013-1085-2","article-title":"Aptamers: multifunctional molecules for biomedical research","volume":"91","author":"Banerjee","year":"2013","journal-title":"J. Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation therapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"26369","DOI":"10.1074\/jbc.274.37.26369","article-title":"Antiproliferative activity of G-rich oligonucleotides correlates with protein binding","volume":"274","author":"Bates","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","article-title":"Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer","volume":"86","author":"Bates","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/nat.2014.0522","article-title":"Identification of epithelial ovarian tumor-specific aptamers","volume":"25","author":"Benedetto","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/842037","article-title":"Screening for Cervical Cancer Using Automated Analysis of PAP-Smears","volume":"2014","author":"Bengtsson","year":"2014","journal-title":"Comput. Math. Methods Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/oli.2008.0177","article-title":"Antimetastatic potential of PAI-1-specific RNA aptamers","volume":"19","author":"Blake","year":"2009","journal-title":"Oligonucleotides"},{"key":"B12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2018.08.004","article-title":"Application of aptamers for in vivo molecular imaging and theranostics","volume":"134","author":"Bouvier-M\u00fcller","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.coph.2010.06.009","article-title":"Development of aptamer therapeutics","volume":"10","author":"Bunka","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"46659\u2013","DOI":"10.1038\/srep46659","article-title":"Aptamer-mediated impairment of EGFR-integrin \u03b1v\u03b23 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers","volume":"7","author":"Camorani","year":"2017","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1038\/s41598-019-44388-9","article-title":"Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells","volume":"9","author":"Carvalho","year":"2019","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5030049","article-title":"Aptamer Cell-Based Selection: Overview and Advances","volume":"5","author":"Catuogno","year":"2017","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ph9040069","article-title":"Aptamer-Mediated Targeted Delivery of Therapeutics: An Update","volume":"9","author":"Catuogno","year":"2016","journal-title":"Pharmaceuticals"},{"key":"B18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.tibtech.2010.07.005","article-title":"Targeting cancer cells with nucleic acid aptamers","volume":"28","author":"Cerchia","year":"2010","journal-title":"Trends Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1039\/c5nr07831h","article-title":"Tumor cell-specific photothermal killing by SELEX-derived DNA aptamer-targeted gold nanorods","volume":"8","author":"Chandrasekaran","year":"2016","journal-title":"Nanoscale"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1604\u2013","DOI":"10.1182\/blood.V110.11.1604.1604","article-title":"Activity and Mechanism of Action of AS1411 in Acute Myeloid Leukemia Cells","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122079","article-title":"Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy","volume":"17","author":"Chen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/IJN.S188003","article-title":"In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model","volume":"14","author":"Chen","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0160822","DOI":"10.1371\/journal.pone.0160822","article-title":"Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14","volume":"11","author":"Cho","year":"2016","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.1560","article-title":"Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors","volume":"27","author":"Dassie","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2014.04.055","article-title":"Aptamer binding assays for proteins: the thrombin example\u2013a review","volume":"837","author":"Deng","year":"2014","journal-title":"Anal. Chim. Acta"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/cbr.1999.14.5","article-title":"Perceptions of Herceptin\u00ae: A Monoclonal Antibody for the Treatment of Breast Cancer","volume":"14","author":"Dillman","year":"1999","journal-title":"Cancer Biother. Radiopharmaceut."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1021\/acs.jproteome.8b00122","article-title":"Advances in the Study of Aptamer\u2013Protein Target Identification Using the Chromatographic Approach","volume":"17","author":"Drabik","year":"2018","journal-title":"J. Proteome Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymeth.2011.02.002","article-title":"Lee D-k. Nucleic acid aptamers targeting cell-surface proteins","volume":"54","author":"Dua","year":"2011","journal-title":"Methods"},{"key":"B29","doi-asserted-by":"publisher","first-page":"36436","DOI":"10.18632\/oncotarget.9262","article-title":"Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging","volume":"7","author":"Duan","year":"2016","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e24071","DOI":"10.1371\/journal.pone.0024071","article-title":"A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death","volume":"6","author":"Esposito","year":"2011","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/cbic.200300663","article-title":"Spiegelmers: biostable aptamers","volume":"4","author":"Eulberg","year":"2003","journal-title":"Chembiochem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0164288","DOI":"10.1371\/journal.pone.0164288","article-title":"Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis","volume":"11","author":"Fortenberry","year":"2016","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0173050","DOI":"10.1371\/journal.pone.0173050","article-title":"Aptamers provide superior stainings of cellular receptors studied under super-resolution microscopy","volume":"12","author":"Gomes de Castro","year":"2017","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"48644","DOI":"10.1074\/jbc.M104651200","article-title":"Tenascin-C aptamers are generated using tumor cells and purified protein","volume":"276","author":"Hicke","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10010009","article-title":"Current Advances in Aptamers for Cancer Diagnosis and Therapy","volume":"10","author":"Hori","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4155\/tde.10.109","article-title":"Nanoparticles and toxicity in therapeutic delivery: the ongoing debate","volume":"2","author":"Hossain","year":"2011","journal-title":"Ther. Deliv."},{"key":"B40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/cr.2015.7","article-title":"Characterization and target identification of a DNA aptamer that labels pluripotent stem cells","volume":"25","author":"Hou","year":"2015","journal-title":"Cell Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e31970","DOI":"10.1371\/journal.pone.0031970","article-title":"Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro","volume":"7","author":"Hu","year":"2012","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1039\/c4lc00587b","article-title":"An on-chip Cell-SELEX process for automatic selection of high-affinity aptamers specific to different histologically classified ovarian cancer cells","volume":"14","author":"Hung","year":"2014","journal-title":"Lab. Chip."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1038\/mtna.2016.73","article-title":"Targeting Insulin Receptor with a Novel Internalizing Aptamer","volume":"5","author":"Iaboni","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10450","DOI":"10.1021\/bi00200a028","article-title":"Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor","volume":"33","author":"Jellinek","year":"1994","journal-title":"Biochemistry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1126\/science.7510417","article-title":"High-resolution molecular discrimination by RNA","volume":"263","author":"Jenison","year":"1994","journal-title":"Sci. (N. Y. NY)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.25958","article-title":"Aptamers in the Therapeutics and Diagnostics Pipelines","volume":"8","author":"Kaur","year":"2018","journal-title":"Theranostics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23040830","article-title":"Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents","volume":"23","author":"Kim","year":"2018","journal-title":"Molecules"},{"key":"B49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/B978-0-323-48452-7.00007-X","article-title":"Chapter 7 - Anti\u2013Vascular Endothelial Growth Factor Therapy for Diabetic Eye Disease","volume-title":"Current Management of Diabetic Retinopathy","author":"Klein","year":"2018"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24193598","article-title":"Inside the Black Box: What Makes SELEX Better","volume":"24","author":"Komarova","year":"2019","journal-title":"Molecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4062\/biomolther.2013.085","article-title":"Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/nat.2012.0347","article-title":"Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells","volume":"22","author":"Kotula","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"18902","DOI":"10.1073\/pnas.0509069102","article-title":"A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165","volume":"102","author":"Lee","year":"2005","journal-title":"Proc.  Natl. Acad. Sci.  U. States America"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.7150\/thno.17069","article-title":"Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1039\/C8BM00787J","article-title":"Differentiating breast cancer molecular subtypes using a DNA aptamer selected against MCF-7 cells","volume":"6","author":"Liu","year":"2018","journal-title":"Biomater. Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1039\/C4NR00018H","article-title":"Enhancing endosomal escape for nanoparticle mediated siRNA delivery","volume":"6","author":"Ma","year":"2014","journal-title":"Nanoscale"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020215","article-title":"Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens","volume":"22","author":"Mallikaratchy","year":"2017","journal-title":"Molecules"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/anie.201006630","article-title":"Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects","volume":"51","author":"Mascini","year":"2012","journal-title":"Angewandte Chem. Int. Ed."},{"key":"B59","doi-asserted-by":"publisher","first-page":"748913\u2013","DOI":"10.1155\/2012\/748913","article-title":"Challenges and opportunities for small molecule aptamer development","volume":"2012","author":"McKeague","year":"2012","journal-title":"J. Nucleic Acids"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9060069","article-title":"Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers","volume":"9","author":"Mercier","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bios.2016.08.028","article-title":"Biosensors for breast cancer diagnosis: A review of bioreceptors, biotransducers and signal amplification strategies","volume":"88","author":"Mittal","year":"2017","journal-title":"Biosens Bioelectron"},{"key":"B62","first-page":"4744","article-title":"Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e39595","DOI":"10.1371\/journal.pone.0039595","article-title":"III. Remyelination Induced by a DNA Aptamer in a Mouse Model of Multiple Sclerosis","volume":"7","author":"Nastasijevic","year":"2012","journal-title":"PloS One"},{"key":"B64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081683","article-title":"Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes","volume":"18","author":"Ni","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010003","article-title":"Aptamers Chemistry: Chemical Modifications and Conjugation Strategies","volume":"25","author":"Odeh","year":"2019","journal-title":"Molecules"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10020047","article-title":"Bioapplications of Cell-SELEX-Generated Aptamers in Cancer Diagnostics, Therapeutics, Theranostics and Biomarker Discovery: A Comprehensive Review","volume":"10","author":"Pang","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"26934","DOI":"10.18632\/oncotarget.25260","article-title":"Aptamers: novelty tools for cancer biology","volume":"9","author":"Pereira","year":"2018","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.molonc.2015.03.012","article-title":"Mechanistic studies of anticancer aptamer AS1411 reveal a\u00a0novel role for nucleolin in regulating Rac1 activation","volume":"9","author":"Reyes-Reyes","year":"2015","journal-title":"Mol. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy","volume":"9","author":"Roccaro Aldo","year":"2014","journal-title":"Cell Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest. New Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2018.04.007","article-title":"Aptamer chemistry","volume":"134","author":"R\u00f6thlisberger","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2019-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-803547-4.00001-X","article-title":"Chapter 1 - Current Trends in Cancer Therapy","volume-title":"Cardio-Oncology","author":"Sekhon","year":"2017"},{"key":"B76","doi-asserted-by":"publisher","first-page":"11838","DOI":"10.1073\/pnas.0602615103","article-title":"Aptamers evolved from live cells as effective molecular probes for cancer study","volume":"103","author":"Shangguan","year":"2006","journal-title":"Proc.  Natl. Acad. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejps.2012.10.014","article-title":"Therapeutic RNA aptamers in clinical trials","volume":"48","author":"Sundaram","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10930-016-9653-2","article-title":"Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins","volume":"35","author":"Tabarzad","year":"2016","journal-title":"Protein J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.surg.2011.05.015","article-title":"Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells","volume":"150","author":"Talbot","year":"2011","journal-title":"Surgery"},{"key":"B81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-4939-1538-5_11","article-title":"Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells","volume":"1218","author":"Thiel","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bios.2014.09.026","article-title":"Aptamers as a replacement for antibodies in enzyme-linked immunosorbent assay","volume":"64","author":"Toh","year":"2015","journal-title":"Biosens Bioelectron"},{"key":"B83","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Sci. (N. Y. NY)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1021\/ac500466x","article-title":"Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment","volume":"86","author":"Van Simaeys","year":"2014","journal-title":"Anal. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2009.06.069","article-title":"Nuclear drug delivery to target tumour cells","volume":"625","author":"Wagstaff","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.2174\/092986711797189565","article-title":"Improving the stability of aptamers by chemical modification","volume":"18","author":"Wang","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.2174\/092986711797189637","article-title":"Aptamer-based fluorescent biosensors","volume":"18","author":"Wang","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091851","article-title":"Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer","volume":"18","author":"Wu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7150\/thno.10202","article-title":"Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e12662","DOI":"10.1111\/cpr.12662","article-title":"Potent anti-angiogenesis and anti-tumour activity of pegaptanib-loaded tetrahedral DNA nanostructure","volume":"52","author":"Xie","year":"2019","journal-title":"Cell Proliferation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/17460441.2011.537321","article-title":"Strategies for the discovery of therapeutic aptamers","volume":"6","author":"Yang","year":"2011","journal-title":"Expert Opin. Drug Discovery"},{"key":"B92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-813689-8.00001-X","article-title":"Chapter 1 - Treatment strategies in cancer from past to present","volume-title":"Drug Targeting and Stimuli Sensitive Drug Delivery Systems","author":"Yildizhan","year":"2018"},{"key":"B93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.addr.2018.07.003","article-title":"Aptamers: Uptake mechanisms and intracellular applications","volume":"134","author":"Yoon","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1541-7786.MCR-16-0462","article-title":"Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis","volume":"15","author":"Yoon","year":"2017","journal-title":"Mol. Cancer Res. MCR"},{"key":"B95","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/nnm.13.80","article-title":"Aptamer-conjugated gold nanoparticles for bioanalysis","volume":"8","author":"Zhang","year":"2013","journal-title":"Nanomed. (Lond)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201603990","article-title":"A Smart Responsive Dual Aptamers-Targeted Bubble-Generating Nanosystem for Cancer Triplex Therapy and Ultrasound Imaging","volume":"13","author":"Zhao","year":"2017","journal-title":"Small (Weinheim  Der Bergstrasse Germany)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B98","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cmdc.201402312","article-title":"Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy","volume":"10","author":"Zhu","year":"2015","journal-title":"ChemMedChem"},{"key":"B99","doi-asserted-by":"publisher","first-page":"20979","DOI":"10.3390\/molecules201219739","article-title":"DNA Aptamers in the Diagnosis and Treatment of Human Diseases","volume":"20","author":"Zhu","year":"2015","journal-title":"Molecules"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1021\/acs.bioconjchem.6b00746","article-title":"Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer","volume":"28","author":"Zhu","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1021\/acs.jafc.8b01006","article-title":"Selection, Identification, and Binding Mechanism Studies of an ssDNA Aptamer Targeted to Different Stages of E. coli O157:H7","volume":"66","author":"Zou","year":"2018","journal-title":"J. Agric. Food Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01115\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T08:44:20Z","timestamp":1595839460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01115\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":101,"alternative-id":["10.3389\/fphar.2020.01115"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.01115","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"article-number":"1115"}}